Reinvigorating AMR resilience: leveraging CRISPR–Cas technology potentials to combat the 2024 WHO bacterial priority pathogens for enhanced global health security—a systematic review DOI Creative Commons
Olalekan John Okesanya, Mohamed Mustaf Ahmed, Jerico Bautista Ogaya

et al.

Tropical Medicine and Health, Journal Year: 2025, Volume and Issue: 53(1)

Published: April 2, 2025

Abstract Background Antimicrobial resistance (AMR) poses a global health threat, particularly in low- and middle-income countries (LMICs). Clustered regularly interspaced short palindromic repeats (CRISPR)–Cas system technology offers promising tool to combat AMR by targeting disabling genes WHO bacterial priority pathogens. Thus, we systematically reviewed the potential of CRISPR–Cas address AMR. Methods This systematic review adhered Preferred Reporting Items for Systematic Reviews Meta-Analyses (PRISMA) guidelines. A comprehensive literature search was conducted using Scopus PubMed databases, focusing on publications from 2014 June 2024. Keywords included “CRISPR/Cas,” “antimicrobial resistance,” “pathogen.” The eligibility criteria required original studies involving CRISPR/Cas systems that targeted Data were extracted eligible studies, qualitatively synthesized, assessed bias Joanna Briggs Institute (JBI)-standardized tool. Results 48 revealed diverse systems, including CRISPR–Cas9, CRISPR–Cas12a, CRISPR–Cas3, various genes, such as blaOXA-232, blaNDM, blaCTX-M, ermB, vanA, mecA , fosA3 blaKPC mcr-1, which are responsible carbapenem, cephalosporin, methicillin, macrolide, vancomycin, colistin, fosfomycin resistance. Some have explored role CRISPR virulence gene suppression, enterotoxin tsst1 iutA Staphylococcus aureus Klebsiella pneumoniae . Delivery mechanisms include bacteriophages, nanoparticles, electro-transformation, conjugative plasmids, demonstrate high efficiency vitro vivo. CRISPR-based diagnostic applications demonstrated sensitivity specificity, with detection limits low 2.7 × 10 2 CFU/mL, significantly outperforming conventional methods. Experimental reported significant reductions resistant populations complete suppression strains. Engineered phagemid particles plasmid-curing been shown eliminate IncF cured plasmids carrying vanA mcr-1 blaNDM 94% efficiency, restore antibiotic susceptibility. Gene re-sensitization strategies used susceptibility E. coli blaKPC-2-mediated carbapenem MDR bacteria. Whole-genome sequencing bioinformatics tools provided deeper insights into CRISPR-mediated defense mechanisms. Optimization enhanced gene-editing efficiencies, offering approach tackling high-priority Conclusions has across While promising, challenges optimizing vivo delivery, mitigating resistance, navigating ethical-regulatory barriers must be addressed facilitate clinical translation.

Language: Английский

Genetic mutations associated with severe respiratory diseases DOI Creative Commons
Alexey D. Moshkin, Kristina A. Stolbunova, Alina D. Matsvay

et al.

South of Russia ecology development, Journal Year: 2025, Volume and Issue: 19(4), P. 28 - 40

Published: Jan. 21, 2025

Aim. To analyze existing data on the impact of mutations in human genome pathogenesis respiratory viral infections and to discuss their relevance clinical practice. The primary objectives include describing mechanisms genetic mutations, reviewing examples genes that affect susceptibility disease severity evaluating prospects for testing personalized medicine.Research factors influencing demonstrates significant progression outcomes. For instance, IFITM3 gene, which plays a crucial role limiting influenza virus replication, along with its rs12252‐C polymorphism, is linked severe cases influenza. Similarly, TLR7 gene are associated manifestations COVID‐19, particularly males. These findings underscore importance identify individuals at heightened risk emphasize potential medicine enhance patient Additionally, it essential consider interplay between environmental as well social determinants health.This review examines influence progression. It can significantly course these infections. integrating into practice efficiency diagnosis, prognosis treatment emphasized.

Language: Английский

Citations

0
Development and optimization of multiplex PCR for rapid detection of type I-F1 and type I-F2 Cas cluster genes in Acinetobacter baumannii DOI

Gulshan Yadav,

Amit Sharma,

Umesh Prasad Sah Hathi

et al.

Biologicals, Journal Year: 2025, Volume and Issue: 90, P. 101824 - 101824

Published: March 13, 2025

Language: Английский

Citations

0
Innovative Strategies for Combating Multidrug-Resistant Tuberculosis: Advances in Drug Delivery Systems and Treatment DOI Creative Commons
Omobolanle A. Omoteso, Adewale Oluwaseun Fadaka, Roderick B. Walker

et al.

Microorganisms, Journal Year: 2025, Volume and Issue: 13(4), P. 722 - 722

Published: March 24, 2025

Multidrug-resistant tuberculosis (MDR-TB) is a significant public health challenge globally, exacerbated by the limited efficacy of existing therapeutic approaches, prolonged treatment duration, and severe side effects. As drug resistance continues to emerge, innovative delivery systems strategies are critical combating this crisis. This review highlights molecular mechanisms underlying drugs in Mycobacterium tuberculosis, such as genetic mutation, efflux pump activity, biofilm formation, contributing persistence difficulty eradicating MDR-TB. Current options, including second-line drugs, offer effectiveness, prompting need for innovation advanced therapies systems. The progression discovery has resulted approval therapeutics, bedaquiline delamanid, amongst other promising candidates under investigation. However, overcoming limitations traditional remains challenge. Nanotechnology emerged solution, with nanoparticle-based offering improved bioavailability targeted controlled release delivery, particularly pulmonary targeting intracellular macrophages. Furthermore, development inhalable formulations potential nanomedicines bypass presents novel approach enhancing efficacy. Moreover, adjunctive therapies, immune modulation host-directed being explored improve outcomes. Immunotherapies, cytokine TB vaccines, complementary use antibiotics Personalized medicine leveraging genomic profiling both pathogen host, promise optimizing regimens minimizing resistance. underscores importance multidisciplinary combining discovery, system development, address complexities treating Continued innovation, global collaboration, diagnostics essential developing practical, accessible, affordable treatments

Language: Английский

Citations

0
Reinvigorating AMR resilience: leveraging CRISPR–Cas technology potentials to combat the 2024 WHO bacterial priority pathogens for enhanced global health security—a systematic review DOI Creative Commons
Olalekan John Okesanya, Mohamed Mustaf Ahmed, Jerico Bautista Ogaya

et al.

Tropical Medicine and Health, Journal Year: 2025, Volume and Issue: 53(1)

Published: April 2, 2025

Abstract Background Antimicrobial resistance (AMR) poses a global health threat, particularly in low- and middle-income countries (LMICs). Clustered regularly interspaced short palindromic repeats (CRISPR)–Cas system technology offers promising tool to combat AMR by targeting disabling genes WHO bacterial priority pathogens. Thus, we systematically reviewed the potential of CRISPR–Cas address AMR. Methods This systematic review adhered Preferred Reporting Items for Systematic Reviews Meta-Analyses (PRISMA) guidelines. A comprehensive literature search was conducted using Scopus PubMed databases, focusing on publications from 2014 June 2024. Keywords included “CRISPR/Cas,” “antimicrobial resistance,” “pathogen.” The eligibility criteria required original studies involving CRISPR/Cas systems that targeted Data were extracted eligible studies, qualitatively synthesized, assessed bias Joanna Briggs Institute (JBI)-standardized tool. Results 48 revealed diverse systems, including CRISPR–Cas9, CRISPR–Cas12a, CRISPR–Cas3, various genes, such as blaOXA-232, blaNDM, blaCTX-M, ermB, vanA, mecA , fosA3 blaKPC mcr-1, which are responsible carbapenem, cephalosporin, methicillin, macrolide, vancomycin, colistin, fosfomycin resistance. Some have explored role CRISPR virulence gene suppression, enterotoxin tsst1 iutA Staphylococcus aureus Klebsiella pneumoniae . Delivery mechanisms include bacteriophages, nanoparticles, electro-transformation, conjugative plasmids, demonstrate high efficiency vitro vivo. CRISPR-based diagnostic applications demonstrated sensitivity specificity, with detection limits low 2.7 × 10 2 CFU/mL, significantly outperforming conventional methods. Experimental reported significant reductions resistant populations complete suppression strains. Engineered phagemid particles plasmid-curing been shown eliminate IncF cured plasmids carrying vanA mcr-1 blaNDM 94% efficiency, restore antibiotic susceptibility. Gene re-sensitization strategies used susceptibility E. coli blaKPC-2-mediated carbapenem MDR bacteria. Whole-genome sequencing bioinformatics tools provided deeper insights into CRISPR-mediated defense mechanisms. Optimization enhanced gene-editing efficiencies, offering approach tackling high-priority Conclusions has across While promising, challenges optimizing vivo delivery, mitigating resistance, navigating ethical-regulatory barriers must be addressed facilitate clinical translation.

Language: Английский

Citations

0